BioSpecifics Technologies Corp (NASDAQ:BSTC)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. They presently have a $65.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $72.00. HC Wainwright’s price objective would suggest a potential upside of 47.16% from the stock’s current price.

Other analysts also recently issued research reports about the company. BidaskClub downgraded BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a research note on Friday, August 18th. Zacks Investment Research raised BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.

Shares of BioSpecifics Technologies Corp (BSTC) traded up $0.54 on Monday, reaching $44.17. The company had a trading volume of 20,700 shares, compared to its average volume of 26,563. The company has a market cap of $313.67, a P/E ratio of 27.44 and a beta of 1.64. BioSpecifics Technologies Corp has a 52 week low of $41.95 and a 52 week high of $58.79.

BioSpecifics Technologies Corp (NASDAQ:BSTC) last issued its earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.01. The company had revenue of $6.52 million for the quarter, compared to the consensus estimate of $6.59 million. BioSpecifics Technologies Corp had a return on equity of 19.11% and a net margin of 42.40%. equities analysts predict that BioSpecifics Technologies Corp will post 1.59 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioSpecifics Technologies Corp’s (BSTC) “Buy” Rating Reaffirmed at HC Wainwright” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/13/biospecifics-technologies-corp-bstc-given-new-65-00-price-target-at-hc-wainwright.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSTC. American International Group Inc. grew its holdings in BioSpecifics Technologies Corp by 7.1% during the 1st quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 222 shares in the last quarter. Alliancebernstein L.P. grew its holdings in BioSpecifics Technologies Corp by 401.8% during the 1st quarter. Alliancebernstein L.P. now owns 40,820 shares of the biopharmaceutical company’s stock valued at $2,237,000 after buying an additional 32,685 shares in the last quarter. Vanguard Group Inc. grew its holdings in BioSpecifics Technologies Corp by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 197,424 shares of the biopharmaceutical company’s stock valued at $10,819,000 after buying an additional 1,879 shares in the last quarter. Geode Capital Management LLC grew its holdings in BioSpecifics Technologies Corp by 16.7% during the 1st quarter. Geode Capital Management LLC now owns 66,059 shares of the biopharmaceutical company’s stock valued at $3,619,000 after buying an additional 9,462 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in BioSpecifics Technologies Corp by 7.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 247,114 shares of the biopharmaceutical company’s stock valued at $13,541,000 after buying an additional 17,774 shares in the last quarter. Institutional investors and hedge funds own 53.92% of the company’s stock.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.